Phase 2 study shows improved quality of life in patients with Crohn's disease, suggesting effective treatment potential.
Treatment with mirikizumab was associated with significantly improved quality of life and patient-reported disease severity sustained through week 104 in patients with moderately-to-severely active Crohn's disease in this phase 2 study (NCT02891226).
No takes yet. Share an insight, caveat, or question.
Jairath et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: